Canada Pension Plan Investment Board Grows Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Canada Pension Plan Investment Board increased its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 20.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 167,100 shares of the medical equipment provider’s stock after buying an additional 28,300 shares during the quarter. Canada Pension Plan Investment Board owned 0.24% of Lantheus worth $14,949,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in LNTH. Reinhart Partners LLC. boosted its stake in shares of Lantheus by 9.9% during the 4th quarter. Reinhart Partners LLC. now owns 1,366,873 shares of the medical equipment provider’s stock worth $122,280,000 after acquiring an additional 123,282 shares during the last quarter. Swedbank AB raised its holdings in Lantheus by 53.3% in the 4th quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider’s stock worth $99,054,000 after purchasing an additional 385,000 shares during the period. Portolan Capital Management LLC lifted its position in Lantheus by 21.1% during the fourth quarter. Portolan Capital Management LLC now owns 812,630 shares of the medical equipment provider’s stock valued at $72,698,000 after purchasing an additional 141,749 shares in the last quarter. Raymond James Financial Inc. bought a new stake in Lantheus during the fourth quarter valued at about $36,183,000. Finally, Boston Partners grew its holdings in Lantheus by 57.5% during the fourth quarter. Boston Partners now owns 400,797 shares of the medical equipment provider’s stock valued at $36,201,000 after purchasing an additional 146,268 shares during the period. 99.06% of the stock is currently owned by institutional investors.

Lantheus Stock Performance

LNTH stock opened at $101.32 on Monday. The company has a market capitalization of $6.94 billion, a PE ratio of 16.86 and a beta of 0.20. The company’s fifty day moving average price is $95.39 and its 200-day moving average price is $95.38. Lantheus Holdings, Inc. has a one year low of $62.59 and a one year high of $126.89.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.23). The company had revenue of $391.11 million for the quarter, compared to the consensus estimate of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. On average, research analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Mary Anne Heino sold 53,107 shares of the firm’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the transaction, the director now directly owns 440,399 shares of the company’s stock, valued at approximately $41,551,645.65. This trade represents a 10.76 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the company’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the sale, the chief financial officer now directly owns 113,860 shares in the company, valued at approximately $11,445,207.20. The trade was a 8.07 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 63,109 shares of company stock valued at $6,016,046 in the last quarter. 1.50% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research firms have recently weighed in on LNTH. JMP Securities reaffirmed a “market outperform” rating and set a $112.00 price objective on shares of Lantheus in a research report on Tuesday, January 14th. Truist Financial lifted their price target on shares of Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a report on Thursday, February 27th. Finally, B. Riley decreased their price objective on shares of Lantheus from $127.00 to $122.00 and set a “buy” rating on the stock in a research report on Friday, March 21st. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, Lantheus presently has an average rating of “Moderate Buy” and a consensus price target of $129.43.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.